argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
614.76
+14.25 (2.37%)
Apr 25, 2025, 4:00 PM EDT - Market closed
argenx SE Revenue
In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth. argenx SE had revenue of $757.39M in the quarter ending December 31, 2024, with 81.26% growth.
Revenue (ttm)
$2.25B
Revenue Growth
+77.22%
P/S Ratio
16.54
Revenue / Employee
$1,406,007
Employees
1,599
Market Cap
37.18B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
ARGX News
- 14 days ago - FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting - Benzinga
- 14 days ago - argenx Announces Annual General Meeting of Shareholders on May 27, 2025 - GlobeNewsWire
- 15 days ago - US FDA approves syringe version of Argenx's immune disorder drug - Reuters
- 15 days ago - argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire
- 18 days ago - argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP - GlobeNewsWire
- 21 days ago - Stock Picks From Seeking Alpha's March 2025 New Analysts - Seeking Alpha
- 7 weeks ago - argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting - GlobeNewsWire
- 2 months ago - argenx SE (ARGX) Q4 2024 Earnings Call Transcript - Seeking Alpha